Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
YM BioSciences (NY: YMI)
2.940 USD  UNCHANGED
Last Price  /  Updated: 6:40 PM EST, Feb 8, 2013  /  Add to My Watchlist      
View: Quote Chart Options News SEC Filings
Press releases about YM BioSciences
 
< Previous 1 2 3 4 5 6 Next >
Gilead Sciences completa la adquisición de YM BioSciences
February 11, 2013
from Business Wire Spanish
Gilead Sciences completes acquisition of YM BioSciences
February 08, 2013
from PR Newswire
Gilead Sciences Completes Acquisition of YM BioSciences
February 08, 2013
from Business Wire News Releases
YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2013
February 07, 2013
from PR Newswire
YM BioSciences Announces Receipt of Final Court Order Approving the Plan of Arrangement with Gilead Sciences
February 05, 2013
from PR Newswire
YM BioSciences Shareholders Approve Plan of Arrangement with Gilead Sciences
January 31, 2013
from PR Newswire
Free Research Reports on CIM, JRCC, HOV and YMI Issued by the Bedford Report
January 21, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
Biotech Industry Expected to Experience More M&A Activity in 2013
January 21, 2013
Five Star Equities Provides Stock Research on BG Medicine and YM BioSciences Read More
from Marketwired News Releases
YM BioSciences Inc. Plan of Arrangement with Gilead Sciences, Inc. Endorsed by Leading Independent Proxy Advisors ISS and Glass Lewis
January 18, 2013
from PR Newswire
YM BioSciences Announces Record Date for Previously Announced Plan of Arrangement
December 21, 2012
from PR Newswire
Gilead Sciences adquiere YM BioSciences
December 14, 2012
from Business Wire Spanish
Biotech Industry Skyrockets in 2012 as FDA New Drug Approval Rate Increases
December 13, 2012
Five Star Equities Provides Stock Research on Sucampo Pharmaceuticals, Inc. and YM BioSciences Inc. Read More
from Marketwired News Releases
Free Research Reports on CSTR, MSFT, SCMP and YMI Issued by the Bedford Report
December 13, 2012
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
IIROC Trade Resumption - YM BioSciences Inc.
December 12, 2012
from Newsfile Corp News Releases
IIROC Trade Halt - YM BioSciences Inc.
December 12, 2012
from Newsfile Corp News Releases
Gilead Sciences to Acquire YM Biosciences
December 12, 2012
from PR Newswire
Gilead Sciences to Acquire YM BioSciences
December 12, 2012
from Business Wire News Releases
YM BioSciences Reports Phase I/II Data for JAK Inhibitor CYT387 in Myelofibrosis at ASH 2012
December 09, 2012
from PR Newswire
YM BioSciences Reports Divestiture of Nimotuzumab Assets by CIMYM
December 03, 2012
from PR Newswire
YM BioSciences Announces Election of Dr. Kapil Dhingra to its Board of Directors
November 20, 2012
from PR Newswire
YM BioSciences Reports Operational and Financial Results for the First Quarter of Fiscal 2013
November 09, 2012
from PR Newswire
FDA Considering Faster Approval Process for Developers of Drugs for Deadly or Debilitating Diseases
November 06, 2012
The Paragon Report Provides Stock Research on XOMA and YM BioSciences Read More
from Marketwired News Releases
YM BioSciences JAK Inhibitor CYT387 Produces Meaningful Reductions of Splenomegaly and Durable Transfusion Independence Responses
November 05, 2012
from PR Newswire
YM BioSciences Reports CYT387 Phase I/II Results Selected for Oral Presentation at ASH2012 Conference
October 11, 2012
from PR Newswire
YM BioSciences Reports Fiscal 2012 Operational and Financial Results
September 21, 2012
from PR Newswire
YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012
May 11, 2012
from PR Newswire
YM BioSciences Raises US$80.5 Million from Public Offering
February 29, 2012
from PR Newswire
Rodman & Renshaw, LLC Acts as Co-Manager to YM Biosciences Inc. in $70 Million Public Offering of Common Shares
February 27, 2012
from Business Wire News Releases
YM BioSciences Prices $70 Million Public Offering of Common Shares
February 24, 2012
from PR Newswire
YM BioSciences Announces Proposed Public Offering of Common Shares
February 23, 2012
from PR Newswire
< Previous 1 2 3 4 5 6 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here